Acute patient‐reported outcomes in B‐cell malignancies treated with axicabtagene ciloleucel

Chimeric antigen receptor T‐cell therapy with axicabtagene ciloleucel (axi‐cel) has considerably improved survival in adults with relapsed/refractory large B‐cell lymphoma. This study reports patient‐reported outcomes (PROs) such as quality of life (QOL) and toxicity in the first 90 days after treat...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoogland, Aasha I., Jayani, Reena V., Collier, Aaron, Irizarry‐Arroyo, Nathaly, Rodriguez, Yvelise, Jain, Michael D., Booth‐Jones, Margaret, Hyland, Kelly A., James, Brian W., Barata, Anna, Bachmeier, Christina A., Chavez, Julio C., Khimani, Farhad, Krivenko, Gabriel S., Lazaryan, Aleksandr, Liu, Hien D., Nishihori, Taiga, Pinilla‐Ibarz, Javier, Shah, Bijal D., Abidi, Muneer, Locke, Frederick L., Jim, Heather S. L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7957158/
https://www.ncbi.nlm.nih.gov/pubmed/33641257
http://dx.doi.org/10.1002/cam4.3664

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7957158/
https://www.ncbi.nlm.nih.gov/pubmed/33641257
http://dx.doi.org/10.1002/cam4.3664

Ejemplares similares